Capital increase registered and listing of new shares

Posted on Sep 9, 2019

Oslo, Norway, 9 September 2019. Reference is made to the previous announcements by PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) in respect of the issuance of 40,000 new shares following exercise of employee share options in the Company. The share capital increase resolved by the Board of Directors following the share option exercise […]

Mandatory notification regarding trade of shares

Posted on Aug 30, 2019

Borkenholm AS has on 29 August 2019 bought 4,000 shares in PCI Biotech Holding ASA (“PCI Biotech”) at an average price of NOK 26.90 per share. Borkenholm AS is a related party to board member Hilde Furberg. After the transaction, Hilde Furberg and her related parties holds 4,000 shares in PCI Biotech. This information is […]

Second quarter and first half 2019 results

Posted on Aug 28, 2019

Oslo (Norway), 28 August 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its second quarter and first half 2019 result. Please find enclosed the report and presentation. First patient enrolled into the pivotal fimaCHEM “RELEASE” study, successful clinical proof-of-concept of fimaVACC and extension of the fimaNAc collaboration with a large […]